Featured News

SAN DIEGO - VedaBio, a pioneering biotechnology company transforming molecular detection, today announced the appointment of Valerie Dixon, CFO of Cleveland Diagnostics, as the first independent member of its Board of Directors.

Groundwork starts before launch: demand, operator economics, clinic training and pricing, all settled with a network of 78 health systems and 300+ centers before FDA clearance.

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a Series A extension alongside a strategic agreement with Siemens Healthineers. Together, these commitments total up to $25 million.

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based technologies in diagnostic applications.

SAN DIEGO - VedaBio, a pioneering biotechnology company at the forefront of molecular detection, today announced the appointment of Randy Rasmussen, Ph.D., to its Board of Directors.

SAN DIEGO, Calif., September 4, 2024 – VedaBio, a biotechnology company leading a paradigm shift in molecular detection, today announced the appointment of G. Brett Robb, Ph.D., as Senior Scientific Director and Head of CRISPR Science.

VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today announced that Frédéric Sweeney, PhD, has been appointed President and Chief Executive Officer.

SAN DIEGO, Calif., November 7, 2023 — VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today announced the formation of its scientific advisory board (SAB) comprised of world class academic and industry experts.

VedaBio launched with initial funding of over $40 million to advance a platform designed to deliver gold standard accuracy without target amplification, with analytical times in seconds to minutes and massive multiplexing capabilities.